Temporal Dynamics of the No-Reflow Phenomenon on Serial Perfusion MRI After Thrombectomy

动力学(音乐) 医学 灌注 磁共振成像 心脏病学 放射科 脑血管循环 生物医学工程 灌注扫描 核医学 核磁共振
作者
Felix Ng,Samantha Rivet,Leonid Churilov,Vincent N. Thijs,Mark W. Parsons,Patricia Desmond,Vijay Venkatraman,SJ Davis,Peter J. Mitchell,Bruce Campbell
出处
期刊:Neurology [Lippincott Williams & Wilkins]
卷期号:106 (7): e214673-e214673 被引量:1
标识
DOI:10.1212/wnl.0000000000214673
摘要

BACKGROUND AND OBJECTIVES: The no-reflow phenomenon, observed in up to 30% of patients with ischemic stroke despite technically successful thrombectomy, is associated with poor outcomes. However, its temporal evolution remains uncharacterized. Understanding its progression is essential to inform the development of adjunctive therapies aimed at improving outcomes after recanalization. The objective of this study was to characterize the temporal dynamics of no-reflow using serial post-thrombectomy MR perfusion imaging. METHODS: In a multicenter prospective observational study, 67 consecutive adult patients with acute anterior large vessel occlusion underwent serial post-thrombectomy perfusion MRI at 2 hours (time point 1, TP1) and 24-48 hours (time point 2, TP2) after the procedure. Key exclusions were inability to tolerate MRI, expanded Treatment in Cerebral Ischemia (eTICI) scores <2c, and missing or poor-quality imaging. The primary outcome was the presence of no-reflow at TP1 and/or TP2, defined as visually detectable hypoperfusion within the infarct with >15% interside median relative cerebral blood volume or flow reduction after eTICI 2c-3 angiographic reperfusion. No-reflow was assessed globally (across the entire diffusion-weighted imaging-positive lesion at TP2) and within 2 subregions (early ischemic core and infarct growth). The associations between no-reflow patterns, infarct growth, and favorable clinical outcome (modified Rankin Scale [mRS] scores 0-1 at 3 months) were examined as exploratory analyses. RESULTS: = 0.03). DISCUSSION: No-reflow manifests early after technically successful thrombectomy and frequently persists, possibly contributing to infarct growth and worse patient outcomes. Cases of resolution and progression suggest a dynamic and reversible pathology, potentially amenable to timely treatment. TRIAL REGISTRATION INFORMATION: ACTRN12624000629538.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
陈陈完成签到,获得积分10
刚刚
Finger发布了新的文献求助10
刚刚
1秒前
杨嘉璐完成签到,获得积分10
1秒前
翁可兰完成签到 ,获得积分10
1秒前
2秒前
旺旺小多发布了新的文献求助10
2秒前
Ada完成签到,获得积分10
3秒前
DezhiShi发布了新的文献求助10
3秒前
月落星沉完成签到 ,获得积分10
3秒前
4秒前
4秒前
5秒前
翁可兰发布了新的文献求助10
5秒前
思源应助整齐芷文采纳,获得10
5秒前
xjc23应助任性的乘风采纳,获得30
5秒前
Lucas应助整齐芷文采纳,获得10
5秒前
Ava应助整齐芷文采纳,获得10
6秒前
FashionBoy应助整齐芷文采纳,获得10
6秒前
传奇3应助整齐芷文采纳,获得10
6秒前
6秒前
金桔希子完成签到,获得积分10
6秒前
lyx完成签到 ,获得积分10
7秒前
zzl发布了新的文献求助10
7秒前
7秒前
8秒前
8秒前
8秒前
9秒前
123456发布了新的文献求助10
9秒前
Ava应助ghhhn采纳,获得10
9秒前
10秒前
11秒前
11秒前
12秒前
单纯凝雁完成签到,获得积分10
12秒前
乔垣结衣发布了新的文献求助10
13秒前
14秒前
打打应助smartfairy采纳,获得10
14秒前
yy发布了新的文献求助10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Prompt Engineering for Clinicians: Harnessing AI in Everyday Medical Practice 600
Electrode Potentials 550
REAL-WORLD EFFICACY AND GENOMIC LANDSCAPE OF POLATUZUMA VEDOTIN-BASED FIRST-LINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: A FOCUS ON TP53 MUTATIONS AND TREATMENT RESPONSE 500
Handbook of Luminescence Dating 500
Safety Pharmacology 500
《KNN基无铅压电陶瓷电学性能优化与物理机理研究》 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 计算机科学 化学工程 生物化学 物理 内科学 复合材料 催化作用 光电子学 物理化学 电极 细胞生物学 基因 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 6957825
求助须知:如何正确求助?哪些是违规求助? 8641008
关于积分的说明 18324414
捐赠科研通 6404539
什么是DOI,文献DOI怎么找? 3084557
关于科研通互助平台的介绍 2131914
邀请新用户注册赠送积分活动 2061239